We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Abbott Laboratories | NYSE:ABT | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.47 | -0.44% | 105.50 | 107.16 | 105.91 | 106.43 | 4,096,958 | 01:00:00 |
Abbott Laboratories Inc. on Wednesday posted foreign-currency driven revenue declines in its latest quarter, though it also raised its annual guidance and said it saw constant-currency gains across all of its segments.
Overall revenue fell 0.2% while operational revenue, which factors out currency changes, increased 5.1%.
For the year, Abbott said it expects adjusted earnings per share of $2.14 to $2.24, up from previous guidance of $2.10 to $2.20, which was sharply below analysts' expectations at the time.
Abbott shares rose 1.2% to $44.37 in premarket trading. Shares have risen 9.7% in the last three months.
For the quarter, the company posted a profit of $316 million, or 21 cents a share, down from $2.29 billion, or $1.51 a share, a year earlier. The year-prior period included a $1.74 billion gain from an asset sale. Excluding that and other items, earnings per share were 41 cents, down from 47 cents a year prior.
Revenue decreased to $4.89 billion from $4.9 billion.
Analysts surveyed by Thomson Reuters forecast adjusted per-share earnings of 39 cents on revenue of $4.78 billion.
Sales edged up 0.1% in its nutrition segment, its largest. Recently launched infant and toddler GMO-free baby food and formula and premium baby formula products in China drove a 4.3% increase on a constant-currency basis.
In its diagnostics unit, sales increased 2.3% nominally and 6.9% on a constant-currency basis as gains in its infectious disease testing business were offset by the planned scale down of its genetics business.
In its non-U. S. established pharmaceuticals unit, sales fell 1.0% but gained 11% when excluding currency fluctuations. Performance was lead by India where it had double-digit growth across several areas, including women's health, gastroenterology, and cardio-metabolics.
Sales in its medical devices segment fell 2.4% but grew 0.5% in constant-currency. The company said "competitive and market dynamics" lead diabetes treatment sales in the U.S. to plummet 32%.
In March, Abbott said its Absorb dissolving heart stent received a positive review from a Food and Drug Administration panel, paving the way for potential approval in the U.S. later this year. It also recently received approval in Europe to use a technologically improved blood sugar monitoring system in children and teens.
Write to Austen Hufford at austen.hufford@wsj.com
(END) Dow Jones Newswires
April 20, 2016 09:25 ET (13:25 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Abbott Laboratories Chart |
1 Month Abbott Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions